Gap 27 (Synonyms: Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile ) |
| Catalog No.GP10119 |
Gap 27 is a peptide (Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile) derived from connexin43 (Cx43) and is a selective gap junction blocker.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 198284-64-9
Sample solution is provided at 25 µL, 10mM.
Gap 27 is a peptide (Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile) derived from connexin43 (Cx43) and is a selective gap junction blocker[1, 2]. Gap 27 specifically acts on this protein by mimicking a part of the Cx43 structure, thereby inhibiting intercellular communication mediated by Cx43[3]. Gap junctions are channel structures on adjacent cell membranes that allow small molecules to be directly transferred between cells and are essential for coordinating cell group activities[4].
In vitro, Gap 27 (500µM) treatment of rat osteoclasts cultured on bovine bone slices for 48h significantly reduced the survival rate of osteoclasts and the number of TRAP-positive mononuclear and multinuclear rat osteoclasts[5]. Gap 27 (0.1mM) treatment of primary human corneal epithelial cells (HCEC) enhanced wound closure of HCEC in vitro[6].
In vivo, Gap 27 (1µg/kg) treated with osmotic micropumps for 4 weeks in rats with an arteriovenous fistula model (AV-Shunt) significantly slowed the progression of cardiac function deterioration and significantly improved cardiac function in rats[7].
References:
[1] De Vuyst E, Boengler K, Antoons G, et al. Pharmacological modulation of connexin‐formed channels in cardiac pathophysiology[J]. British journal of pharmacology, 2011, 163(3): 469-483.
[2] Sathiyanadan K, Alonso F, Domingos-Pereira S, et al. Targeting endothelial Connexin37 reduces angiogenesis and decreases tumor growth[J]. International journal of molecular sciences, 2022, 23(6): 2930.
[3] Ribeiro-Rodrigues T M, Martins-Marques T, Morel S, et al. Role of connexin 43 in different forms of intercellular communication–gap junctions, extracellular vesicles and tunnelling nanotubes[J]. Journal of cell science, 2017, 130(21): 3619-3630.
[4] Maeda S, Tsukihara T. Structure of the gap junction channel and its implications for its biological functions[J]. Cellular and Molecular Life Sciences, 2011, 68(7): 1115-1129.
[5] Ilvesaro J, Tavi P, Tuukkanen J. Connexin-mimetic peptide Gap 27 decreases osteoclastic activity[J]. BMC musculoskeletal disorders, 2001, 2(1): 10.
[6] Elbadawy H M, Mirabelli P, Xeroudaki M, et al. Effect of connexin 43 inhibition by the mimetic peptide Gap27 on corneal wound healing, inflammation and neovascularization[J]. British journal of pharmacology, 2016, 173(19): 2880-2893.
[7] Lucero C M, Andrade D C, Toledo C, et al. Cardiac remodeling and arrhythmogenesis are ameliorated by administration of Cx43 mimetic peptide Gap27 in heart failure rats[J]. Scientific Reports, 2020, 10(1): 6878.
| Cell experiment [1]: | |
Cell lines | Osteoclasts |
Preparation Method | Mechanically harvested osteoclasts from the long bones of 1 or 2-day-old Sprague-Dawley rat pups were allowed to attach to sonicated bovine cortical bone slices (0.5cm2). After 30min, the non-attached cells were rinsed away, and the remaining cells on the bone slices were cultured in three groups: control, heptanol and Gap 27. The control group was cultured in DMEM (Dulbecco's modified Eagle's medium) buffered with 20mM Hepes and containing 0.84g of sodium bicarbonate/liter, 2mM L-glutamine, 100 IU of penicillin/ml, 100µg of streptomycin/ml and 7% heatinactivated fetal calf serum (FCS), which medium will be later referred to as DMEM-FCS. The heptanol group was cultured in medium with 0.15% ethanol and 3mM heptanol in DMEM-FCS. Third group of bone cells, Gap 27 peptide group, was cultured with Gap 27 peptide at concentration 500µM in DMEM-FCS. In all the three groups cells were cultured for 48h, after which the cultures were stopped by fixing the cells and bone slices with freshly made or refrigerated 3% paraformaldehyde (PFA) and 2% sucrose in PBS for 10min at room temperature. The cells were stained for tartrate-resistant acid phosphatase (TRAP), a commonly accepted marker of osteoclasts, using a TRAP kit according to the manufacturer's instruction. |
Reaction Conditions | 500µM; 48h |
Applications | Gap 27 caused a remarked decrease in the number of both TRAP-positive mononuclear and multinucleated rat osteoclasts cultured on bovine bone slices. |
| Animal experiment [2]: | |
Animal models | Sprague-Dawley rats |
Preparation Method | Highoutput heart failure was induced by volume overload using the arterio-venous fistula model (AV-Shunt) in adult male rats. Four weeks after AV-Shunt surgery, the Cx43 mimetic peptide Gap 27 (1µg/kg) or scrambled peptide, were administered via osmotic minipumps (AV-ShuntGap 27 or AV-ShuntScr) for 4 weeks. Cardiac volumes, arrhythmias, function and remodeling were determined at 8 weeks after AV-Shunt surgeries. |
Dosage form | 1µg/kg; 4 week; osmotic minipumps |
Applications | Gap 27 treatment significantly slowed the progression of cardiac deterioration in rats, and intraventricular pressure-volume loop measurements showed a significant improvement in cardiac function. |
References: | |
| Cas No. | 198284-64-9 | SDF | |
| Synonyms | Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile | ||
| Chemical Name | Gap 27 | ||
| Canonical SMILES | CCC(C)C(C(=O)NC(C(C)CC)C(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)O)NC(=O)C2CCCN2C(=O)C(CCCN=C(N)N)NC(=O)C(CO)N | ||
| Formula | C60H101N15O17 | M.Wt | 1304.55 |
| Solubility | ≥65.25mg/mL in DMSO, ≥5mg/mL in Water | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 766.5 μL | 3.8327 mL | 7.6655 mL |
| 5 mM | 153.3 μL | 766.5 μL | 1.5331 mL |
| 10 mM | 76.7 μL | 383.3 μL | 766.5 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *